Clinical Trial on Sequential Immunization of Recombinant COVID-19 Vaccine (CHO Cells,NVSI-06-08) and Inactivated COVID-19 Vaccine (Vero Cells) in Population Aged 18 Years and Above

NCT05069129 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

UNKNOWN

Status

1848

Enrollment

INDUSTRY

Sponsor class

Conditions

COVID-19 Pneumonia
Coronavirus Infections

Interventions

BIOLOGICAL: Recombinant COVID-19 Vaccine (CHO cell，NVSI-06-08)
BIOLOGICAL: Inactivated COVID-19 vaccine (Vero cells)
BIOLOGICAL: 3 doses Recombinant COVID-19 Vaccine (CHO cell，NVSI-06-08)

Sponsor

National Vaccine and Serum Institute, China

Collaborators

[object Object]
[object Object]
[object Object]